A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage Treatment in Refractory or Relapsed Small Cell Lung Cancer
10.3779/j.issn.1009-3419.2013.09.06
- VernacularTitle:伊立替康联合奈达铂对比联合顺铂二线治疗复发或难治性小细胞肺癌的疗效及毒副作用回顾分析
- Author:
YU SHUFEI
1
;
WANG YAN
;
HU XINGSHENG
;
WANG HONGYU
;
HAO XUEZHI
;
XU JIANPING
;
LI JUNLING
;
ZHANG XIANGRU
;
SHI YUANKAI
Author Information
1. 中国医学科学院肿瘤医院肿瘤内科
- Keywords:
Lung neoplasms;
Irinotecan;
Platinum;
Relapsed
- From:
Chinese Journal of Lung Cancer
2013;(9):470-475
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective At present no standard second-line combination has been established for recurrent small cell lung cancer (SCLC). hTerefore we evaluate the effcacy and safety of irinotecan in combination with nedapla-tin/cisplatin against refractory or relapsed small cell lung cancer. Methods In this retrospective study, we analyzed the data of 1,140 patients who diagnosed small cell lung cancer at our hospital from April 2009 to April 2012. Of all the patients, 34 patients were treated with irinotecan and nedaplatin (irinotecan 60 mg/m2 on days 1, 8 nedaplatin 85 mg/m2 day 1, every 3 weeks) , and 20 patients were treated with irinotecan and cisplatin (irinotecan 60 mg/m2 on days 1, 8 cisplatin 75 mg/m2 day 1, every 3 weeks) as the second-line treatment. Prognostic factors of overall survival (OS) were estimated by Kaplan-Meier and Cox's Regression-proportional hazards model. Results Of all the 54 eligible patients, median progression free survival (PFS) was 4.9 months, and median OS was 13.3 months. Median PFS was 5.4 months for irinotecan plus nedaplatin (IN) and 4.9 months for irinotecan plus cisplatin (IC), respectively (P=0.465). Median OS was 14.3 months and 13.3 months, respectively (P=0.704). In multivariate analysis, ECOG PS, number of metastases and cycles of chemotherapy were independent prognostic factors. hTe toxicities were mild, while toxicity proifle was slightly different for each of the arms:hematologic toxicity was higher in IN group, and diarrhea was higher in IC group. Conclusion Irinotecan plus platinum is effective and tolerable for refractory and relapsed small cell lung cancer. Irinotecan plus nedaplatin is non-inferior to irinotecan plus cisplatin in terms of effcacy and safety.
